Prognostic factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer: a retrospective study

Purpose First-line choice of therapy is critical as it affects treatment decisions in later lines in patients with metastatic colorectal cancer (mCRC). We assessed changes in renal function for 1 year among patients diagnosed with mCRC who received first-line chemotherapy. We aimed to analyze the prognostic factors and effect of each chemotherapy regimen on the renal function of the patients. Methods We retrospectively investigated patients with mCRC who were treated with a standard triplet regimen (FOLFOX/FOLFIRI with bevacizumab/cetuximab) in the first-line setting at Korea University Anam Hospital from 2015 to 2020. We checked renal function at 3-month intervals for 12 months. We calculated changes in eGFR (oeGFR, estimated glomerular filtration rate) and compared them with clinical factors such as age, sex, chronic disease, body mass index (BMI), disease status, baseline proteinuria, and first-line chemotherapy regimen. Results Among 472 patients with mCRC, the median eGFR at baseline was 90.9 mL/min/1.73 m(2); it was significantly lower (80.1 mL/min/1.73 m(2), p < 0.001) at 12 months after chemotherapy initiation. Particularly, the eGFR of patients treated with FOLFIRI + bevacizumab was 74.9 mL/min/1.73 m(2). The 1-year incidence rate of acute kidney injury (AKI) was 9.1%, with the lowest occurrence in patients receiving FOLFOX/cetuximab (2.1%) and the highest in those receiving FOLFIRI + bevacizumab (19.2%). Renal dysfunction was more frequent with FOLFIRI + bevacizumab as compared to the other regimens. Additionally, old age, low BMI, and proteinuria at baseline were also associated with a decreased eGFR. Conclusions These findings can serve as important factors when selecting the first-line chemotherapy regimen for patients with mCRC.

Automated summary

This study investigated the changes in renal function among mCRC patients who received first-line chemotherapy and analyzed the prognostic factors and the effect of each chemotherapy regimen on renal function. The study found that renal function significantly decreased after 12 months of chemotherapy, with FOLFIRI + bevacizumab causing more frequent renal dysfunction. Older age, lower BMI, and baseline proteinuria were also associated with decreased renal function.